InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.03
(
-0.12%
)
Bitcoin
66,567.33
(
-0.11%
)
Post# of 252209
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

flatlander_60048

Send PM Follow Ignore
Followers 10
Posts 476
Boards Moderated 0
Alias Born 02/10/2006

flatlander_60048

Re: None

Monday, 10/17/2011 10:16:51 PM

Monday, October 17, 2011 10:16:51 PM

Post# of 252209
Gilenya press release

Seems like 50% of patients completing the 5 yr trial might be a bit low given the advantage of oral delivery. I wonder to what extent the discontinuationa are due to side effects vs. medical community steering patients away until more data is collected.

FL
http://www.novartis.com/newsroom/media-releases/en/2011/1555145.shtml
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up